1) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編:特発性間質性肺炎診断と治療の手引き,改訂第2版,南江堂,p3,2011
2) Kohno N, Kyoizumi S, Awaya Y, et al : New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6.Chest 96:68-73,1989
3) Ishikawa N, Hattori N, Yokoyama A, et al : Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig 50:3-13,2012
4) 大西広志,横山彰仁:IPFのバイオマーカー―間質性肺炎のバイオマーカーKL-6.呼吸器内科 19:590-596,2011
5) Inoue Y, Barker E, Daniloff E, et al : Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis. Am J Respir Crit Care Med 156:109-115,1997
6) Inoue Y, Trapnell BC, Tazawa R, et al : Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 177:752-762,2008
7) Kobayashi J, Kitamura S : KL-6 : a serum marker for interstitial pneumonia. Chest 108:311-315,1995
8) Inoue Y, Nishimura K, Shiode M, et al : Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis. Tuber Lung Dis 76:230-233,1995
9) Ohnishi H, Yokoyama A, Kondo K, et al : Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 165:378-381,2002
10) Yokoyama A, Kondo K, Nakajima M, et al : Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 11:164-168,2006
11) Yokoyama A, Kohno N, Hamada H, et al : Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 158:1680-1684,1998
12) 高橋弘毅,白鳥正典,千葉弘文:IPFのバイオマーカー―SP-D,SP-A.呼吸器内科 19:597-604,2011
13) Aono Y, Ledford JG, Mukherjee S, et al : Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. Am J Respir Crit Care Med 185:525-536,2012
14) Honda Y, Kuroki Y, Matsuura E, et al : Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 152:1860-1866,1995
15) 横山彰仁:血液検査の読み方.間質性肺炎を究める(滝澤始編),メジカルビュー社,pp38-42,2012
16) 早稲田優子,安井正英,市川由加里,他:感染性肺疾患とSP-A,SP-D,KL-6.第70回間質性肺疾患研究会討議記録,pp15-23,2004
17) Takahashi H, Fujishima T, Koba H, et al : Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 162:1109-1114,2000
18) Takahashi H, Shiratori M, Kanai A, et al : Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D. Respirology 11:S51-S54,2006
19) Kinder BW, Brown KK, McCormack FX, et al : Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 135:1557-1563,2009
20) 井上義一,岸潤,新井徹,他:肺間質性病変とKL-6,SP-A,SP-D―肺の画像から見て.日本胸部臨床 61:125-133,2002
21) 新井徹,井上義一,深水玲子,他:特発性間質性肺炎における血清KL-6,SP-D濃度と画像所見(HRCT)の検討.第70回間質性肺疾患研究会討議記録,pp36-43,2004
22) Ichiyasu H, Ichikado K, Yamashita A, et al : Pneumocyte biomarkers KL-6 and surfactant protein D reflect the distinct findings of high-resolution computed tomography in nonspecific interstitial pneumonia. Respiration 83:190-197,2012
23) Sakamoto K, Taniguchi H, Kondoh Y, et al : Serum KL-6 in fibrotic NSIP : Correlations with physiologic and radiologic parameters. Respir Med 104:127-133,2010
24) 高橋弘毅,白鳥正典,北田順也,他:間質性肺炎に対するcyclosporin-A長期使用例の検討.厚生労働科学研究:特発性肺線維症の予後改善を目指したサイクロスポリン+ステロイド治療ならびにN-アセチルシステイン吸入療法に関する臨床研究,平成19年度班研究報告書,pp32-36,2008